The following video is part of our "Motley Fool Conversations" series, in which analyst John Reeves discusses topics across the investing world.
Over the next several weeks we'll be looking at each of the components of the Dow Jones Industrial Average and subjecting each of them to a dividend checkup. Today, we're looking at Pfizer. Pfizer is one of the top drug companies in the world, and its big pharma competitors include Merck and Novartis. Pfizer is up around 5% for the year, which is slightly below the Dow average return of around 6% for the year; Merck is up 10.5%. Pfizer had its dividend cut in 2009, but it increased it by 10% at the beginning of this year. Currently it delivers a yield of 3.8%, compared with 2.9% for the Dow as whole. Competitor Merck's yield is slightly higher at 4.0%; Johnson & Johnson is slightly lower at 3.6%. Pfizer is an extremely strong company that delivers solid returns on capital, and has a decent pipeline. It does face fierce competition from Merck, Teva, and Novartis, but it looks like a pretty good bet for the long term.
Pfizer is a very attractive income-generating stock. If you're interested in learning more about some additional, high-yielding stocks, The Motley Fool has compiled a special free report outlining our top nine dependable, dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here to discover the winners we've picked.
At the time thisarticle was published John Reeveshas no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson and National Oilwell Varco.Motley Fool newsletter services recommendJohnson & Johnson, National Oilwell Varco, and Pfizer. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.